MOC — Molecure SA Income Statement
0.000.00%
- PLN106.93m
- PLN95.87m
- PLN6.02m
Annual income statement for Molecure SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2021 December 31st | R2022 December 31st | R2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.17 | 1.61 | 3.65 | 1.39 | 6.02 |
| Cost of Revenue | |||||
| Gross Profit | 0.984 | 0.51 | -0.449 | -2.01 | 4.23 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 14.9 | 18.4 | 35.8 | 33.7 | 22.6 |
| Operating Profit | -13.8 | -16.8 | -32.1 | -32.3 | -16.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.6 | -15.3 | -28.4 | -31.5 | -15.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.6 | -15.3 | -28.4 | -31.5 | -15.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.6 | -15.3 | -28.4 | -31.5 | -15.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.6 | -15.3 | -28.4 | -31.5 | -15.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.792 | -1.09 | -1.69 | -1.56 | -0.767 |
| Dividends per Share |